The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Synergistic effects of caspase inhibitors and MK‐801 in brain injury after transient focal cerebral ischaemia in mice
Open accessAbstract
Excitotoxic and apoptotic mechanisms have been implicated in the pathophysiology of cerebral ischaemia. Both MK‐801, an NMDA receptor antagonist, or peptide inhibitors of the caspase family (z‐VAD.FMK and z‐DEVD.FMK), protect mouse brain from ischaemic cell damage. In this study, we examined whether these drugs which act via distinct mechanisms, afford even greater neuroprotection when given in combination following 2 h MCA occlusion (filament model) and 18 h reperfusion. Given alone as pretreatment, MK‐801 (1, 3 and 5 mg kg−1, but not 0.3 mg kg−1, i.p.) decreased infarct size by 34–75%. When injected 1 h after occlusion and before reperfusion, 3 mg kg−1 reduced injury but not when administered 1 h after reperfusion. Pretreatment with a subthreshold dose of MK‐801 (0.3 mg kg−1) plus a subthreshold dose of z‐VAD.FMK (27 ng) or z‐DEVD (80 ng) significantly decreased infarct size by 29 and 30%, respectively, and enhanced neurological function. Administering a subthreshold dose of z‐VAD.FMK (27 ng) or z‐DEVD.FMK (80 ng) as pretreatment extended the time window for MK‐801 (3 mg kg−1) by 2 h from 1 h before reperfusion to at least 1 h after reperfusion. Pretreating with a subthreshold dose of MK‐801 (0.3 mg kg−1) extended the time window for z‐DEVD.FMK (480 ng) from 1 h after reperfusion to at least 3 h after reperfusion. We conclude that caspase inhibitors which putatively block apoptotic cell death and inhibit cytokine production and the NMDA antagonist MK‐801 act synergistically and prolong their respective therapeutic windows in cerebral ischaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bederson, J. B., Pitts, L. H., Tsuji, M., Nishimura, M. C., Davis, R. L., & Bartkowski, H. (1986) · Stroke · doi:10.1161/01.str.17.3.472 · Cited by 2,681
MacDermott, A. B., Mayer, M. L., Westbrook, G. L., Smith, S. J., & Barker, J. L. (1986) · Nature · doi:10.1038/321519a0 · Cited by 1,835
Cited by
Ischemic Cell Death in Brain Neurons
Lipton, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1431 · Cited by 3,043
Apoptotic Mechanisms After Cerebral Ischemia
Broughton, B. R. S., Reutens, D. C., & Sobey, C. G. (2009) · Stroke · doi:10.1161/strokeaha.108.531632 · Cited by 1,266
The changing landscape of ischaemic brain injury mechanisms
Lee, J.-M., Zipfel, G. J., & Choi, D. W. (1999) · Nature · doi:10.1038/399a007 · Cited by 1,102
Activation and Cleavage of Caspase-3 in Apoptosis Induced by Experimental Cerebral Ischemia
Namura, S., Zhu, J., Fink, K., Endres, M., Srinivasan, A., Tomaselli, K. J., Yuan, J., & Moskowitz, M. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-10-03659.1998 · Cited by 893
Self-citationMolecular targets in cerebral ischemia for developing novel therapeutics
Mehta, S. L., Manhas, N., & Raghubir, R. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.11.003 · Cited by 708
Metadata
- Authors
- Ma, J., Endres, M., & Moskowitz, M. A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 1998-06
- Volume
- 124
- Issue
- 4
- Pages
- 756-762
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1997351400
- Cited by
- 163
- References
- 2
- FWCI
- 16.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synergistic effects of caspase inhibitors and MK‐801 in brain injury after transient focal cerebral ischaemia in mice. https://app.cochat.ai/papers/10.1038/sj.bjp.0701871
- The paper
- Ma, J., Endres, M., & Moskowitz, M. A. (1998). Synergistic effects of caspase inhibitors and MK‐801 in brain injury after transient focal cerebral ischaemia in mice. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0701871
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.